Fresh frozen plasma in patients with disseminated intravascular coagulation or in patients with liver diseases.
Disseminated intravascular coagulation (DIC) and liver diseases are complex clinical conditions. Both disorders frequently disturb the finely tuned coagulation and fibrinolysis equilibrium. In DIC, a wide range of underlying disorders can induce a systemic activation of the coagulation system with generation of soluble fibrin, possible deposition of platelet-rich fibrin clots in the microvasculature and subsequent micro- or macroembolism, impaired organ perfusion and organ failure. Such coagulation activation depletes platelets, coagulation factors, and inhibitors and clinically can result in severe, sometimes untreatable bleeding, especially when bone marrow or liver function is diminished or invasive procedures are performed. In addition, a secondary counterbalancing activation of the fibrinolytic system to dissolve microcirculatory clots adds to the bleeding tendency. In conjunction with other options based on prompt and rigorous treatment of the underlying cause of DIC, fresh frozen plasma plays an important role in therapeutic management when overt bleeding is present or anticipated in DIC patients with disturbed coagulation or when an invasive procedure is being planned. In liver disease, factor and inhibitor synthesis in both the coagulation and fibrinolytic system is impaired, both quantitatively and qualitatively. This destabilizes the balance between the two systems. In addition, the clearance of activated coagulation factors and fibrin(ogen) degradation products (FDP) from the systemic circulation is impaired. In patients with liver diseases and acute or imminent bleeding, or before invasive procedures, fresh frozen plasma (FFP) offers advantages over clotting factor concentrates. However, hypervolemia following the required doses of FFP might pose a problem in some liver disease patients.The complex pathophysiology both in DIC and in liver disease requires early diagnosis and adequate management including plasma and platelet substitution after treatment of the underlying disease. Due to the heterogeneity of DIC and liver disease, prospective randomized trials are difficult to perform. Therefore, treatment recommendations are mostly empirical and less evidence-based. Therapy must be accompanied by close and repeated clinical and laboratory monitoring.
Mueller
Markus M
MM
Red Cross Blood Donor Service, Frankfurt am Main, Germany. mmueller@bsdhessen.de
Bomke
Barbara
B
Seifried
Erhard
E
D000818:Animals; D001779:Blood Coagulation Factors / Q000008:administration & dosage / Q000627:therapeutic use; D016913:Blood Component Transfusion; D004211:Disseminated Intravascular Coagulation / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D006487:Hemostasis / Q000502:physiology; D006801:Humans; D008107:Liver Diseases / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D010949:Plasma
D001779:Blood Coagulation Factors